JP2016517877A5 - - Google Patents

Download PDF

Info

Publication number
JP2016517877A5
JP2016517877A5 JP2016511150A JP2016511150A JP2016517877A5 JP 2016517877 A5 JP2016517877 A5 JP 2016517877A5 JP 2016511150 A JP2016511150 A JP 2016511150A JP 2016511150 A JP2016511150 A JP 2016511150A JP 2016517877 A5 JP2016517877 A5 JP 2016517877A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
methyl
tetrahydrofuran
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016511150A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016517877A (ja
JP6263606B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/060945 external-priority patent/WO2014177977A1/en
Publication of JP2016517877A publication Critical patent/JP2016517877A/ja
Publication of JP2016517877A5 publication Critical patent/JP2016517877A5/ja
Application granted granted Critical
Publication of JP6263606B2 publication Critical patent/JP6263606B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016511150A 2013-05-02 2014-04-23 Pde10阻害剤としてのイミダゾ−トリアジン誘導体 Expired - Fee Related JP6263606B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361818650P 2013-05-02 2013-05-02
US61/818,650 2013-05-02
PCT/IB2014/060945 WO2014177977A1 (en) 2013-05-02 2014-04-23 Imidazo-triazine derivatives as pde10 inhibitors

Publications (3)

Publication Number Publication Date
JP2016517877A JP2016517877A (ja) 2016-06-20
JP2016517877A5 true JP2016517877A5 (cg-RX-API-DMAC7.html) 2017-04-13
JP6263606B2 JP6263606B2 (ja) 2018-01-17

Family

ID=50841902

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016511150A Expired - Fee Related JP6263606B2 (ja) 2013-05-02 2014-04-23 Pde10阻害剤としてのイミダゾ−トリアジン誘導体

Country Status (33)

Country Link
US (3) US8933224B2 (cg-RX-API-DMAC7.html)
EP (1) EP2991989B1 (cg-RX-API-DMAC7.html)
JP (1) JP6263606B2 (cg-RX-API-DMAC7.html)
KR (1) KR101770905B1 (cg-RX-API-DMAC7.html)
CN (1) CN105164134B (cg-RX-API-DMAC7.html)
AP (1) AP2015008843A0 (cg-RX-API-DMAC7.html)
AR (1) AR096161A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014261070A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015027760A8 (cg-RX-API-DMAC7.html)
CA (1) CA2910759C (cg-RX-API-DMAC7.html)
CL (1) CL2015003037A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150591A (cg-RX-API-DMAC7.html)
CU (1) CU20150144A7 (cg-RX-API-DMAC7.html)
DK (1) DK2991989T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2015000271A (cg-RX-API-DMAC7.html)
EA (1) EA027936B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP15050110A (cg-RX-API-DMAC7.html)
ES (1) ES2637816T3 (cg-RX-API-DMAC7.html)
GE (1) GEP201706675B (cg-RX-API-DMAC7.html)
MA (1) MA38559B1 (cg-RX-API-DMAC7.html)
MD (1) MD20150103A2 (cg-RX-API-DMAC7.html)
MX (1) MX2015015163A (cg-RX-API-DMAC7.html)
NI (1) NI201500157A (cg-RX-API-DMAC7.html)
NZ (1) NZ712949A (cg-RX-API-DMAC7.html)
PE (1) PE20151940A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015502462A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201508201VA (cg-RX-API-DMAC7.html)
TN (1) TN2015000490A1 (cg-RX-API-DMAC7.html)
TW (1) TWI508966B (cg-RX-API-DMAC7.html)
UA (1) UA111696C2 (cg-RX-API-DMAC7.html)
UY (1) UY35547A (cg-RX-API-DMAC7.html)
WO (1) WO2014177977A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201508968B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111696C2 (uk) * 2013-05-02 2016-05-25 Пфайзер Інк. Похідні імідазотриазину як інгібітори рde10
HRP20220144T1 (hr) 2016-09-09 2022-04-15 Novartis Ag Spojevi i pripravci kao inhibitori endosomskih toll-u sličnih receptora
EP3801499B1 (en) 2018-06-07 2024-02-28 Disarm Therapeutics, Inc. Inhibitors of sarm1
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
BR112022007491A2 (pt) * 2019-10-21 2022-07-12 Sk Biopharmaceuticals Co Ltd Medicamento, composição farmacêutica e método para prevenção, alívio ou tratamento de distúrbio cognitivo, e, uso de um composto de imidazopirimidina ou imidazotriazina
AU2023214467A1 (en) * 2022-02-02 2024-07-11 Katholieke Universiteit Leuven Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
CN117486878A (zh) * 2023-10-27 2024-02-02 扬州市普林斯医药科技有限公司 一种恩那司他的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
JP2007508241A (ja) 2003-07-31 2007-04-05 バイエル・フアーマシユーチカルズ・コーポレーシヨン Pde10a阻害剤を用いる糖尿病および関連障害の処置方法
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US20070167426A1 (en) 2004-06-02 2007-07-19 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
TW200716102A (en) 2005-06-01 2007-05-01 Wyeth Corp Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
US8207370B2 (en) 2006-09-26 2012-06-26 Kaneka Corporation Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
DE102007059723A1 (de) 2007-12-12 2009-06-18 Siemens Medical Instruments Pte. Ltd. Hörvorrichtung mit Batterieklappenmodul
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
JP2011515401A (ja) 2008-03-20 2011-05-19 アムジエン・インコーポレーテツド オーロラキナーゼモジュレーターおよび使用方法
KR101774035B1 (ko) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조[1,2―b]피리다진 유도체 및 PDE10 저해제로서의 그의 용도
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
US20130071415A1 (en) 2010-05-28 2013-03-21 Biocryst Pharmaceuticals, Inc. Heterocyclic Compounds as Janus Kinase Inhibitors
WO2011157793A1 (en) 2010-06-17 2011-12-22 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
AU2012221828C1 (en) * 2011-02-23 2015-10-01 Pfizer Inc. Imidazo[5,1-f][1,2,4]triazines for treatment of neurological disorders
UA111696C2 (uk) * 2013-05-02 2016-05-25 Пфайзер Інк. Похідні імідазотриазину як інгібітори рde10

Similar Documents

Publication Publication Date Title
JP2016517877A5 (cg-RX-API-DMAC7.html)
PH12016501164A1 (en) Heteroaryl substituted nicotinamide compounds
JP2017503867A5 (cg-RX-API-DMAC7.html)
JP2014513139A5 (cg-RX-API-DMAC7.html)
JP2016523270A5 (cg-RX-API-DMAC7.html)
RU2370496C2 (ru) Конденсированные производные пиридина, применимые в качестве антагонистов аденозинового рецептора a2b
HRP20191307T1 (hr) Spojevi heteroaril-piridona i aza-piridona kao inhibitori aktivnosti btk
NZ586579A (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
NZ601128A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
JP2019503337A5 (cg-RX-API-DMAC7.html)
HRP20211864T1 (hr) Inhibitori hetero-halo histonske deacetilaze
HRP20170349T1 (hr) Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
FI4074703T3 (fi) Pyridinyyli-(atsa)indolsulfonamiidit
HRP20191268T1 (hr) Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk
RU2016130932A (ru) Производные хинолона как ингибиторы рецептора фактора роста фибробластов
RU2018138471A (ru) Гетероциклические соединения в качестве ингибиторов киназы RET
TN2016000503A1 (en) Pyrazolopyridines and pyrazolopyrimidines
RU2016140338A (ru) Азаспиро производные в качестве антагонистов trpm8
JP2016505010A5 (cg-RX-API-DMAC7.html)
ME02394B (me) Pirazolohinolinski derivati kao inhibitori pde9
JP2013512953A5 (cg-RX-API-DMAC7.html)
JP2016520116A5 (cg-RX-API-DMAC7.html)
JP2017524702A (ja) CDK阻害剤としての2−アミノ−ピリド[2,3−d]ピリミジン−7(8H)−オン誘導体及びその使用
JP2007523151A5 (cg-RX-API-DMAC7.html)
JP2019536768A5 (cg-RX-API-DMAC7.html)